Global Afamelanotide Industry Size, Market Share, Price and Growth Rate Research Report 2026
On Jan 16, the latest report "Global Afamelanotide Market 2026 by Manufacturers, Regions, Types and Applications, Forecast to 2032" from Global Info Research provides a detailed and comprehensive analysis of the global Afamelanotide market. The report provides both quantitative and qualitative analysis by manufacturers, regions and countries, types and applications. As the market is constantly changing, this report explores market competition, supply and demand trends, and key factors that are causing many market demand changes. The report also provides company profiles and product examples of some of the competitors, as well as market share estimates for some of the leading players in 2026.
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/3403369/afamelanotide
According to our (Global Info Research) latest study, the global Afamelanotide market size was valued at US$ 69.76 million in 2025 and is forecast to a readjusted size of US$ 116 million by 2032 with a CAGR of 7.6% during review period.
Afamelanotide is a synthetic peptide drug, an analog of alpha-melanocyte-stimulating hormone (α-MSH), used as a subcutaneous implant to prevent painful skin reactions from sun exposure in patients with the rare genetic disorder Erythropoietic Protoporphyria (EPP). It works by stimulating melanin (specifically eumelanin) production in the skin, which blocks light and reduces the severe pain, redness, and swelling caused by EPP. Administered as a small implant under the skin, it's released slowly over about two months.
Global production of afanotide is projected to reach 3,000 vials by 2025, with an average price of US,600 per vial. Gross profit margins typically remain at a high level of 70% to 85%.
Afamelanotide is a synthetic analog of melanocyte-stimulating hormone. Its upstream industry chain mainly consists of peptide raw materials and amino acid monomers, solid-phase synthesis resins and reagents, solvents, lyophilization excipients, sterile packaging materials, and bioanalytical testing services. The upstream focus lies in high-purity peptide synthesis and consistent quality control. Downstream demand is highly concentrated in rare disease and niche dermatology treatments, with its primary use in improving phototolerance for patients with erythropoietic protoporphyria. End users are mainly specialized hospitals, rare disease treatment centers, and reimbursement systems. Given the small and clearly defined patient population, downstream stakeholders prioritize clinical efficacy, safety, ease of administration, and long-term adherence. Payment is often supported by public insurance, special funds, or premium commercial insurance, resulting in relatively low price sensitivity but high requirements for clinical evidence. As real-world data accumulates, downstream applications are gradually expanding toward additional photosensitivity-related indications, while remaining focused on specialist channels and academic promotion.
In terms of industry trends, Afamelanotide products are moving toward indication expansion, optimized delivery methods, and stronger real-world evidence generation. Key growth drivers include supportive orphan drug policies, incentives for rare disease development, and increasing advocacy from patient organizations. Major constraints include a limited patient base that caps market size, high development and regulatory costs, complex manufacturing barriers, and strong dependence on a single core product.
This report is a detailed and comprehensive analysis for global Afamelanotide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Afamelanotide market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Subcutaneous Implants、 Injectables、 Transdermal Patches、 Oral Preparations、 Topical Preparations
Market segment by Application: Hematologic Disorders、 Skin Pigmentary Disorders、 Acute Diseases、 Autoimmune Diseases、 Neurodegenerative Diseases
Major players covered: Clinuvel Pharmaceuticals、 Evonik Industries、 Hangzhou Go Top Peptide Biotech、 Zhejiang Hengtengfu、 Wepon
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Afamelanotide product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Afamelanotide, with price, sales quantity, revenue, and global market share of Afamelanotide from 2021 to 2026.
Chapter 3, the Afamelanotide competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Afamelanotide breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment Afamelanotide the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the Afamelanotide sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2025.and Afamelanotide market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Afamelanotide.
Chapter 14 and 15, to describe Afamelanotide sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Afamelanotide
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/3403369/afamelanotide
According to our (Global Info Research) latest study, the global Afamelanotide market size was valued at US$ 69.76 million in 2025 and is forecast to a readjusted size of US$ 116 million by 2032 with a CAGR of 7.6% during review period.
Afamelanotide is a synthetic peptide drug, an analog of alpha-melanocyte-stimulating hormone (α-MSH), used as a subcutaneous implant to prevent painful skin reactions from sun exposure in patients with the rare genetic disorder Erythropoietic Protoporphyria (EPP). It works by stimulating melanin (specifically eumelanin) production in the skin, which blocks light and reduces the severe pain, redness, and swelling caused by EPP. Administered as a small implant under the skin, it's released slowly over about two months.
Global production of afanotide is projected to reach 3,000 vials by 2025, with an average price of US,600 per vial. Gross profit margins typically remain at a high level of 70% to 85%.
Afamelanotide is a synthetic analog of melanocyte-stimulating hormone. Its upstream industry chain mainly consists of peptide raw materials and amino acid monomers, solid-phase synthesis resins and reagents, solvents, lyophilization excipients, sterile packaging materials, and bioanalytical testing services. The upstream focus lies in high-purity peptide synthesis and consistent quality control. Downstream demand is highly concentrated in rare disease and niche dermatology treatments, with its primary use in improving phototolerance for patients with erythropoietic protoporphyria. End users are mainly specialized hospitals, rare disease treatment centers, and reimbursement systems. Given the small and clearly defined patient population, downstream stakeholders prioritize clinical efficacy, safety, ease of administration, and long-term adherence. Payment is often supported by public insurance, special funds, or premium commercial insurance, resulting in relatively low price sensitivity but high requirements for clinical evidence. As real-world data accumulates, downstream applications are gradually expanding toward additional photosensitivity-related indications, while remaining focused on specialist channels and academic promotion.
In terms of industry trends, Afamelanotide products are moving toward indication expansion, optimized delivery methods, and stronger real-world evidence generation. Key growth drivers include supportive orphan drug policies, incentives for rare disease development, and increasing advocacy from patient organizations. Major constraints include a limited patient base that caps market size, high development and regulatory costs, complex manufacturing barriers, and strong dependence on a single core product.
This report is a detailed and comprehensive analysis for global Afamelanotide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Afamelanotide market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Subcutaneous Implants、 Injectables、 Transdermal Patches、 Oral Preparations、 Topical Preparations
Market segment by Application: Hematologic Disorders、 Skin Pigmentary Disorders、 Acute Diseases、 Autoimmune Diseases、 Neurodegenerative Diseases
Major players covered: Clinuvel Pharmaceuticals、 Evonik Industries、 Hangzhou Go Top Peptide Biotech、 Zhejiang Hengtengfu、 Wepon
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Afamelanotide product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Afamelanotide, with price, sales quantity, revenue, and global market share of Afamelanotide from 2021 to 2026.
Chapter 3, the Afamelanotide competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Afamelanotide breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment Afamelanotide the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the Afamelanotide sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2025.and Afamelanotide market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Afamelanotide.
Chapter 14 and 15, to describe Afamelanotide sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Afamelanotide
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
